-Shares of Senseonics (NYSEMKT:SENS) are on the march in Friday’s pre-market action stock after the medtech firm reported positive test results for its glucose-monitoring system. SENS stock was up more than 30% at 8:30 a.m. Eastern.
-SENS stock closed Thursday at $2.05 a share after surging over the past six month. The shares used to trade deep in penny stock territory, below 50 cents through most of 2020.
-Senseonics is focused on developing and commercializing long-term implantable continuous glucose monitoring systems, or CGMs, for patients with diabetes. It is novel in that it can be implanted and then provide data for up to six months.
-Big move comes after the firm said study results for both a primary and secondary glucose sensor — or an SBA sensor — showed promising preliminary results. The study sought to evaluate Senseonics’ Eversense CGM System in patients with diabetes, testing them over a 180-day period. The study is the basis of the pre-market application submissions to the U.S. Food and Drug Administration and to European regulators for a CE mark, the company said.
-SENS stock closed Thursday at $2.05 a share after surging over the past six month. The shares used to trade deep in penny stock territory, below 50 cents through most of 2020.
-Senseonics is focused on developing and commercializing long-term implantable continuous glucose monitoring systems, or CGMs, for patients with diabetes. It is novel in that it can be implanted and then provide data for up to six months.
-Big move comes after the firm said study results for both a primary and secondary glucose sensor — or an SBA sensor — showed promising preliminary results. The study sought to evaluate Senseonics’ Eversense CGM System in patients with diabetes, testing them over a 180-day period. The study is the basis of the pre-market application submissions to the U.S. Food and Drug Administration and to European regulators for a CE mark, the company said.